John M. Goldman

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Stephen G. O’Brien, François Guilhot, Richard A. Larson et al. · New England Journal of Medicine · 2003 · 3.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Medicine, Hematology, Oncology +13

The molecular biology of chronic myeloid leukemia

Michael W. Deininger, John M. Goldman, Junia V. Melo · Blood · 2000 · 1.6K citations

Medicine, Molecular Biology, Oncology +14

Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

Timothy P. Hughes, Jaspal Kaeda, Susan Branford et al. · New England Journal of Medicine · 2003 · 1.2K citations · Full text

Life Sciences, Hematology, Oncology +13

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz et al. · New England Journal of Medicine · 2013 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17